Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Incyte Japan Announces Approval of Minjuvi® in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte Announces European Commission Approval of Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
Incyte Announces Positive CHMP Opinion for Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound
